Skip to main
HCAT

HCAT Stock Forecast & Price Target

HCAT Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 11%
Hold 78%
Sell 0%
Strong Sell 0%

Bulls say

Health Catalyst Inc. is anticipated to sustain high single-digit organic growth due to a combination of new client acquisitions and contractual price escalators, with a long-term margin target of 20%. Recent financial results have exceeded expectations, and the company's Ignite platform is showing signs of traction, indicating potential for improving profitability. Furthermore, the integration of software with professional services uniquely positions Health Catalyst to enhance client outcomes, suggesting a viable pathway for shareholder value creation despite current market challenges.

Bears say

Health Catalyst's financial outlook is hindered by concerns over declining organic revenue, with expectations of a 2-3% year-over-year decrease in 2026 and 14.3% to 11.9% decline anticipated for the first quarter of 2026, which is notably below consensus estimates. Despite a modest 3Q revenue beat, the company's guidance reflects challenges such as client migrations to a lower-cost platform and the restructuring of less-profitable contracts, which may lead to customer attrition and down-selling. Additionally, economic uncertainty and pressure on health systems could exacerbate adverse purchasing conditions, further impacting the company's financial performance.

HCAT has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 11% recommend Buy, 78% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Health Catalyst Inc (HCAT) Forecast

Analysts have given HCAT a Hold based on their latest research and market trends.

According to 9 analysts, HCAT has a Hold consensus rating as of Apr 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Health Catalyst Inc (HCAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.